Palamur Biosciences Faces Scrutiny Amid PETA Allegations, Awaits Official Inspection Report
Mahabubnagar: Palamur Biosciences Pvt. Ltd. (PBS), a leading preclinical research facility in Mahabubnagar, has recently come under public scrutiny following complaints submitted by PETA India. The allegations, reportedly based on claims from a former employee, were widely circulated before PBS was given an opportunity to present its side. In response, a multi-agency inspection involving the Committee for the Purpose of Control and Supervision of Experiments on Animals (CCSEA) and the Animal Welfare Board of India has thoroughly reviewed PBS operations. The organization is now awaiting the committee's official findings.
Despite the controversy, PBS maintains that it operates with full regulatory compliance and transparency. Recognized by international and national bodies such as GLP, CDSCO, AAALAC, and OLAW, PBS has been a cornerstone of India's biomedical innovation ecosystem for over 15 years. It is the country's only large-animal testing facility and one of the few in Southeast Asia, playing a vital role in the development of pharmaceuticals, medical devices, vaccines, and agrochemicals.
PBS is also home to India's first large-animal-based medical device evaluation center, supported by BIRAC under the 'Make in India' and 'Atmanirbhar Bharat' initiatives. It has validated breakthrough technologies such as artificial hearts, dialysis systems, heart valves, and stents—contributing significantly to India's healthcare advancement.
The Directors of PBS emphasized their commitment to ethical research, scientific excellence, and animal welfare, stating, 'We are confident the inspection will confirm our long-standing adherence to the highest standards. Baseless allegations can severely harm India's R&D ecosystem, especially startups that rely on domestic preclinical services.'
PBS has urged media, regulators, and the public to await the official report and engage in discourse based on facts, not speculation, to protect the integrity of India's innovation landscape.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
10 hours ago
- Hans India
Palamur Biosciences Faces Scrutiny Amid PETA Allegations, Awaits Official Inspection Report
Mahabubnagar: Palamur Biosciences Pvt. Ltd. (PBS), a leading preclinical research facility in Mahabubnagar, has recently come under public scrutiny following complaints submitted by PETA India. The allegations, reportedly based on claims from a former employee, were widely circulated before PBS was given an opportunity to present its side. In response, a multi-agency inspection involving the Committee for the Purpose of Control and Supervision of Experiments on Animals (CCSEA) and the Animal Welfare Board of India has thoroughly reviewed PBS operations. The organization is now awaiting the committee's official findings. Despite the controversy, PBS maintains that it operates with full regulatory compliance and transparency. Recognized by international and national bodies such as GLP, CDSCO, AAALAC, and OLAW, PBS has been a cornerstone of India's biomedical innovation ecosystem for over 15 years. It is the country's only large-animal testing facility and one of the few in Southeast Asia, playing a vital role in the development of pharmaceuticals, medical devices, vaccines, and agrochemicals. PBS is also home to India's first large-animal-based medical device evaluation center, supported by BIRAC under the 'Make in India' and 'Atmanirbhar Bharat' initiatives. It has validated breakthrough technologies such as artificial hearts, dialysis systems, heart valves, and stents—contributing significantly to India's healthcare advancement. The Directors of PBS emphasized their commitment to ethical research, scientific excellence, and animal welfare, stating, 'We are confident the inspection will confirm our long-standing adherence to the highest standards. Baseless allegations can severely harm India's R&D ecosystem, especially startups that rely on domestic preclinical services.' PBS has urged media, regulators, and the public to await the official report and engage in discourse based on facts, not speculation, to protect the integrity of India's innovation landscape.
Hindustan Times
a day ago
- Hindustan Times
Two suspected Malaria cases in Gurugram
Gurugram has reported its first two malaria cases this year. The patients are currently stable and under the health department's supervision, according to the district health department's latest bulletin. Malaria, which had almost disappeared from the city, saw a resurgence with two cases in 2024. The detection of two cases this year has prompted the department to stay on high alert, said officials. 'A private laboratory confirmed the malaria cases using a rapid diagnostic kit. While we consider this result credible, the most reliable method for confirmation is the Peripheral Blood Smear (PBS) test, which provides 100% accuracy. We will be using this test for final confirmation. Additionally, we have collected blood samples from the infected's family members to ensure the disease does not spread further,' said Dr Vikas Swami, deputy civil surgeon, Gurugram. To prevent the spread of mosquito-borne diseases like malaria, dengue, and chikungunya, the health department has intensified field activity across the district. This year, over one lakh people have been tested for malaria so far. Meanwhile, 923 blood samples have been collected for dengue testing. On Wednesday, rapid response teams inspected 7,273 houses, out of which 117 were found to have larvae, said health officials. Dengue cases in Gurugram have shown a fluctuating trend over the past three years. In 2024, the city reported 186 cases, a drop from 276 in 2023. The highest count in recent years was in 2022, with 440 cases. Health officials continue to stress the importance of mosquito control and early detection. All Community Health Centre (CHC), Primary Health Centre (PHC) workers, and multipurpose health workers (MPHWs) have been deployed for door-to-door surveillance. Separate teams have also been formed to carry out malaria and dengue inspections, said health officials. 'With the change in weather, we are seeing a rise in fever cases. We are conducting daily anti-larvae drives and involving community groups to keep mosquito breeding in check,' said Dr Swami further adding that NGOs have been issued government-approved malaria ID cards so they can visit residential areas and inspect water bodies freely. Health officials are actively promoting the 'Dry Day' concept across Gurugram where residents are urged to empty water coolers once a week and keep them dry for a day to disrupt the mosquito breeding cycle. 'Mosquito larvae can hatch within seven days in stagnant water, which increases the risk of dengue and chikungunya. We're involving Resident Welfare Associations (RWAs) to help implement Dry Day activities in colonies and societies,' said Dr Swami. Fogging drives are being carried out by the Municipal Corporation of Gurugram (MCG). People are also being advised to regularly change stored water, clean their terraces, and apply mosquito-repellent cream to children before they go outside. As part of vector control, the department has identified 204 water bodies in Gurugram — 160 in rural areas and 44 in urban zones. Gambusia fish, known for feeding on mosquito larvae, have been released into these water bodies to help curb the mosquito population naturally, said health officials.
The Hindu
2 days ago
- The Hindu
Miltenyi Biotec, BIRAC partner to boost cell and gene therapy capabilities
Miltenyi Biotec India and Biotechnology Industry Research Assistance Council (BIRAC) have signed a letter of intent for a collaboration aimed at enhancing India's capabilities in cell and gene therapy through capacity building, advancing clinical research and to solve unmet medical needs by local manufacturing of cell therapies. The LOI was signed at the BIO International Convention 2025, which opened this week in Boston, they said in a joint release on Wednesday. German cellular research, cell therapy and cell manufacturing solutions provider Miltenyi Biotec in February had announced plans for a cell and gene therapy centre of excellence in Hyderabad. The partnership with BIRAC is to build national capabilities and upskill scientific talent by implementing structured training and capacity-building programmes for clinicians, researchers and technicians in CGT manufacturing, analytics, and quality control. It is also to expand translational research efforts through co-development of academic and multi-centre studies and set up point-of-care (PoC) CAR-T centres across India using automated manufacturing platforms to enable cost-effective and scalable access to personalised CGT treatments. Their partnership with also promote targeted cell therapy research and support local innovation through the identification and mentoring of Indian startups thus aligning with the Make in India mission by enhancing domestic production of critical and manufacturing components and by supporting development of national CGT COEs. 'Together, we are exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering,' MiltenyiBiotec India MD Priya Kapoor-Hingorani said.
